Protagonist Therapeutics Inc (PTGX)

Nov 22, 2025

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Times Herald

Nov 22, 2025

Nov 21, 2025

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Daily American

Nov 21, 2025

Nov 21, 2025

Envestnet Asset Management Inc. Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 21, 2025

Nov 20, 2025

Protagonist Therapeutics stock maintains Buy rating at Jefferies on pipeline potential - Investing.com Canada

Nov 20, 2025

Nov 20, 2025

What hedge fund activity signals for Protagonist Therapeutics Inc. stockWall Street Watch & Real-Time Chart Breakout Alerts - newser.com

Nov 20, 2025

Nov 19, 2025

How rising interest rates impact Protagonist Therapeutics Inc. stockRate Hike & Entry Point Strategy Guides - newser.com

Nov 19, 2025

Nov 19, 2025

How Protagonist Therapeutics Inc. stock responds to policy changesTrade Risk Summary & Weekly Top Gainers Trade List - newser.com

Nov 19, 2025

Nov 19, 2025

Is Protagonist Therapeutics Inc. stock entering bullish territoryCPI Data & Advanced Technical Analysis Signals - newser.com

Nov 19, 2025

Nov 19, 2025

What risks investors should watch in Protagonist Therapeutics Inc. stockEarnings Recap Report & Daily Oversold Stock Bounce Ideas - newser.com

Nov 19, 2025

Nov 19, 2025

Is Protagonist Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Summary & Weekly Top Gainers Trade List - newser.com

Nov 19, 2025

Nov 18, 2025

Protagonist Therapeutics (PTGX) Price Target Increased by 16.48% to 91.65 - MSN

Nov 18, 2025

Nov 18, 2025

Protagonist Therapeutics expands scope of peptide therapeutics - Traders Union

Nov 18, 2025

Nov 18, 2025

Protagonist Therapeutics, Inc. $PTGX is Knott David M Jr's 9th Largest Position - MarketBeat

Nov 18, 2025

Nov 18, 2025

Protagonist Therapeutics Opens with 27.21% Gain Amidst Market Decline - Markets Mojo

Nov 18, 2025

Nov 17, 2025

Persistent Asset Partners Ltd Takes Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 17, 2025

Nov 17, 2025

Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Bank of New York Mellon Corp - MarketBeat

Nov 17, 2025

Nov 15, 2025

H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX) - The Globe and Mail

Nov 15, 2025

Nov 15, 2025

How Protagonist Therapeutics Inc. stock reacts to job market dataMarket Movement Recap & AI Powered Market Entry Strategies - newser.com

Nov 15, 2025

Nov 15, 2025

Protagonist Therapeutics, Inc. $PTGX Stock Holdings Trimmed by Aviva PLC - MarketBeat

Nov 15, 2025

Nov 14, 2025

November 2025's Top Value Picks For Potential Market Opportunities - Yahoo Finance

Nov 14, 2025

Nov 14, 2025

Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Jupiter Asset Management Ltd. - MarketBeat

Nov 14, 2025

Nov 13, 2025

Protagonist Therapeutics Inc. stock chart pattern explained2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com

Nov 13, 2025

Nov 13, 2025

135,050 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Nan Fung Trinity HK Ltd. - MarketBeat

Nov 13, 2025

Nov 13, 2025

Profund Advisors LLC Has $1.05 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 13, 2025

Nov 13, 2025

We Think You Can Look Beyond Protagonist Therapeutics' (NASDAQ:PTGX) Lackluster Earnings - 富途牛牛

Nov 13, 2025

Nov 13, 2025

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Central New Jersey News

Nov 13, 2025

Nov 12, 2025

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - York Daily Record

Nov 12, 2025

Nov 12, 2025

How strong is Protagonist Therapeutics Inc. stock revenue growthEarnings Trend Report & Daily Profit Maximizing Tips - newser.com

Nov 12, 2025

Nov 12, 2025

Protagonist Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance - Markets Mojo

Nov 12, 2025

Nov 11, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $98.00 at Citigroup - MarketBeat

Nov 11, 2025

Nov 11, 2025

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Morris County NJ News | Daily Record

Nov 11, 2025

Nov 11, 2025

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Tallahassee Democrat

Nov 11, 2025

Nov 11, 2025

Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq

Nov 11, 2025

Nov 11, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 11, 2025